Additionally, the company presented positive results on its TactiFlex Duo Ablation Catheter, Sensor Enabled, a dual-energy, focal ablation catheter, designed to allow physicians to tailor how they deliver AFib therapy.
“The data for Volt confirms what I see firsthand in the procedure room with this next-generation PFA device. The system’s unique design enables a high degree of freedom from AFib for patients, and its impressive safety profile reduces PFA-specific complications such as hemolysis, which negatively impacts other parts of the body,” said Atul Verma of McGill University Health Centre and McGill University in Canada, who treated patients as part of the VOLT-AF IDE study.